Gilead Sciences, Inc. (NASDAQ: GILD) disclosed detailed 48-week results of its two big phase three clinical trials to evaluate tenofovir alafenamide 25 mg in treatment-naïve and treat-experienced adults with HBeAg-negative, as well as HBeAg-positive chronic hepatitis B infection. The company indicated that both the trial met their primary endpoints of non-interiority to its Viread 300 mg based on the percentage of patients with HBV DNA levels below IU/mL during the treatment period.

Gilead Sciences disclosed that TAF demonstrated enhanced renal and bone laboratory safety parameters compared to Viread. According to the company, discontinuations as a result of adverse events were uncommon in both treatment arms. The medical firm said that the most commonly disclosed adverse events included a headache, upper respiratory tract infection, cough, and nasopharyngitis. The company also pointed out that the adverse events happened at similar rates in patients receiving either TAF or Viread.

Gilead Science's EVP for R&D and Chief Scientific Officer, Norbert Bischofberger, commented, "Chronic hepatitis B infection is a life-threatening disease that can lead to liver failure, liver cancer and death." He added, "With millions of people living with the disease, it remains a significant health concern worldwide. The TAF Phase 3 results presented this week demonstrate its potential to advance the treatment of HBV – offering a similar efficacy profile to Viread with improved bone and renal safety parameters."

On Thursday, shares of the company ended with $1.06 gain.

See more from Benzinga

• Wingstop To Disclose Q1 Results On May 5

• BioTelemetry To Release Q1 Financial Numbers On April 26

• Monotype Image Holdings To Reveal 1Q Financial Results And Conference Call On April 29

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.